harnesses the unique capabilities of the protozoa Tetrahymena
thermophila to produce recombinant proteins for the biopharmaceutical
industry. With our world-class science team, we are rapidly advancing the
knowledge surrounding this important organism and discovering new and important
applications for its use.
We've developed two
breakthrough platform technologies TetraExpress™ and G-SOME™ and are applying
them to advance several nanoparticle-based infectious disease vaccines. Our
influenza program has received support from several federal agencies, including
the National Institute of Allergy and Infectious Diseases (NIAID), and we've
also been funded by the Bill & Melinda Gates Foundation for our project to
develop a transmission blocking malaria vaccine.
Through an active
partnering effort we are working with biopharmaceutical companies to leverage
our SionX™ technology to overexpress human ion channel drug targets. We have
developed unique capabilities to produce immunogen preparations in any of
several formats that are designed to enhance antibody production against the
extracellular portions of the target.